Period January - March · The Group's net sales for the period were SEK 134 (131) million. Adjusted for the divested OTC products, sales were SEK 112 million for the previous year. · EBITDA for the period amounted to SEK 31 (18) million. Adjusted for the divested OTC products, EBITDA for the previous year was SEK 10 million. · Operating profit totalled SEK 25 (11) million. · Profit/loss after tax for the period was SEK 18 (-3) million. · Earnings per share after tax, before and after dilution, for the period were SEK 0.05 (-0.01). Significant events during the period · BioPhausia acquired renewed confidence as the main supplier of parallel- imported pharmaceuticals to Apoteksgruppen. Significant events after the period · On 11 April Medivir AB submitted a public takeover bid for all shares and listed warrants in BioPhausia. [HUG#1516044]
Interim report January-March 2011
| Source: BioPhausia AB